Objective—To determine clinical response and toxic
effects of cis-bis-neodecanoato-trans-R,R-1,2-
diaminocyclohexane platinum (II) (L-NDDP) administered
IV at escalating doses to cats with oral squamous
cell carcinoma (SCC).
Animals—18 cats with oral SCC.
Procedure—Cats that failed to respond to conventional
treatment or had nonresectable tumors were
included. Data included a CBC, serum biochemical
analyses, urinalysis, cytologic examination of a fineneedle
aspirate of enlarged lymph nodes, and thoracic
and oral radiographs for clinical staging. A
starting dose (75 to 100 mg/m2 of L-NDDP) was
administered IV. At 21-day intervals, subsequent
doses increased by the rate of 5 or 10 mg/m2.
Response was evaluated every 21 days by tumor
measurement and thoracic radiography. Quality of
life was assessed by owners, using a performance
Results—On average, cats received 2 treatments.
Toxicoses included an intermittent, acute anaphylactoid-
parasympathomimetic reaction, lethargy or
sedation (≤ 24 hours), inappetence or signs of
depression (≤ 72 hours), mild to moderate increase
in hepatic enzyme activity, and melena. Pulmonary,
renal, or hematopoietic abnormalities were not evident.
Performance status surveys indicated normal
behavior and grooming or decreased activity and
self-care (19/20 assessments), ate well with or
without assistance (15/20), and did not lose weight
(15/20). Median survival time was 59.8 days (mean,
Conclusions and Clinical Relevance—L-NDDP was
ineffective for treatment of cats with oral SCC. None
of the cats had a complete or partial remission.
Acute toxicoses and poor therapeutic response limit
therapeutic usefulness of L-NDDP in cats, unless
dosage, frequency, and administration procedures
can be improved. (Am J Vet Res 2000;61:
Objective—To evaluate safety and efficacy of LDI-100, a preparation containing human chorionic gonadotropin (hCG) and bacillus Calmette-Guerin (BCG), in the treatment of dogs with mast cell tumors and to compare results with those from a control group receiving single-agent vinblastine.
Animals—95 dogs with measurable grade II or III mast cell tumors.
Procedures—Dogs were randomized to receive either LDI-100 (1.35 ng of BCG and 2 units of hCG, SC, q 24 h) or vinblastine (2 mg/m2, IV, q 1 wk) for 6 weeks. Tumors were measured at baseline and day 42, and dogs were monitored for signs of toxicosis. Clinical performance scores were recorded at each visit. Differences in host factors (sex, weight, and age), clinical performance score, tumor response, and adverse events were analyzed.
Results—46 dogs received LDI-100, and 49 dogs received vinblastine. No significant differences were found between the 2 treatment groups with regard to host factors or clinical performance score. Tumor response (≥50% reduction) rates were similar between the LDI-100 and vinblastine group (28.6% and 11.7%, respectively). Dogs in the LDI-100 group had significantly less neutropenia than the vinblastine group.
Conclusions and Clinical Relevance—hCG and BCG have immunomodulatory and antitumor effects against a variety of malignancies in humans and dogs. In this study, LDI-100 provided clinical responses comparable to single-agent vinblastine chemotherapy but without myelosuppression. LDI-100 is a promising new agent that should be further investigated for multimodality therapy of mast cell tumors in dogs.